Article Text

Download PDFPDF
Audit, research and guideline update
The LungPath study: variation in the diagnostic and staging pathway for patients with lung cancer in England
  1. Paul Cane1,
  2. Karen Linklater2,
  3. George Santis3,
  4. Henrik Møller4,
  5. Michael Peake5
  1. 1Department of Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK
  2. 2National Cancer Registration Service, Public Health England, UK
  3. 3Division of Asthma, Allergy and Lung Biology, King's College London, London, UK
  4. 4Department of Cancer Epidemiology and Population Health, King's College London, London, UK
  5. 5Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK
  1. Correspondence to Dr Paul Cane, Department of Cellular Pathology, Guy's and St Thomas’ NHS Foundation Trust, London SE1 7EH, UK; paul.cane{at}


The LungPath project investigated differences in lung cancer diagnostic practice by following the diagnostic pathways of 1507 patients from 19 representative English lung cancer centres. We found large variation in the proportion of patients receiving positron emission tomography-CT scan (range 13%–64%) and endobronchial ultrasound (range 2%–31%). There was also wide variation in the proportion of patients with good performance status who had their tumours histologically confirmed (range 61%–100%). The variation is discussed with reference to current national guidelines and implications for patient care.

  • Lung Cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.